Pluristem Receives Israeli Ministry of Heath Approval to Expand Its Phase II Clinical Trial in Intermittent Claudication to Israel
Pluristem Therapeutics Inc., a leading developer of placenta-based cell therapies, announced today that the Israeli Ministry of Health has approved the company’s request to initiate a Phase II study using its PLacental eXpanded (PLX) cells in the treatment of Intermittent Claudication (IC), a subset of peripheral artery disease (PAD). This approval is part of the company’s previously announced strategy to conduct a multi-national study for this indication. The protocol will be the same one used for the study previously approved...
View full press release